A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Gurioli C, Ortoncelli M, Fabbrocini G, Nettis E, Schena D, Napolitano M, Gola M, Bonzano L, Rossi M, Belloni Fortina A, Balato A, Peris K, Foti C, Guarneri F, Romanelli M, Patruno C, Savoia P, Esposito M, Russo F, Errichetti E, Bianchelli T, Bianchi L, Pellacani G, Feliciani C, Offidani A, Corazza M, Micali G, Milanesi N, Malara G, Chiricozzi A, Tramontana M, Hansel K; DADA - Dupilumab for Atopic Dermatitis of the Adolescence study group.
Stingeni L, et al. Among authors: chiricozzi a.
J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e384-e388. doi: 10.1111/jdv.18648. Epub 2022 Oct 18.
J Eur Acad Dermatol Venereol. 2023.
PMID: 36225088
No abstract available.